Uterine cell proliferation was studied in intact Sprague-Dawley (SD) and Fischer 344 (F344) rats exposed to the antiestrogens tamoxifen (TAM; 5, 10,20, or 40 mg/kg) and toremifene (TOR; 21.2 or 42.4 mg/kg). The antiestrogens were administered to animals via gavage daily for 2 or 12 wk. Uterine proliferation was assessed using markers for the proliferating cell nuclear antigen (PCNA) and by the bromodeoxyuridine (BrdU) method. Diethylstilbestrol (DES) was used as an estrogenic reference compound. The antiestrogens either reduced or prevented changes of myometrial and stromal proliferation indices (PI). TAM and TOR caused a timedependent reduction of endometrial glands without an associated decrease in cell proliferation. In the luminal columnar epithelium, the antiestrogens depressed PCNA PI but enhanced BrdU PI, indicating a low continuous DNA synthesis in otherwise quiescent cells. The antiestrogens induced focal hyperplastic multilayered epithelia with PCNA-positive basal cells along segments of the luminal uterine epithelium. We suggest that this hyperplastic epithelium represents remnants from the glandular epithelium. DES was less efficient in inducing these changes but induced squamous metaplasias in the F344 rats. Uterine effects of the 2 antiestrogens were comparable with the exception of 1 TAM-exposed (40 mg/kg) SD rat that showed squamous metaplasia. F344 rats were more sensitive to the estrogenic action of DES than were the SD rats.
INTRODUCTION
Tamoxifen (TAM) and toremifene (TOR) are closely related triphenylethylene, partial agonistic antiestrogenic compounds designed for the treatment of breast cancer. TAM has been used for more than 20 yr and is currently the most widely used hormonal anticancer drug (37) , whereas TOR was introduced on the worldwide market in the mid 1990s. The clinical doses used in the USA (i.e., 20 mg TAM and 60 mg TOR) have been proved to have similar efficacy and safety profiles in the treatment of metastatic breast cancer in postmenopausal women (17) . An increasing concern regarding TAM has been raised over the last decade because of the reports of an increased risk of endometrial cancer in patients receiving long-term TAM treatment, leading the International Agency for Research on Cancer (21) to classify TAM as a human carcinogen. Employing DNA flow cytometry, TAM-induced endometrial proliferation in premenopausal women seems to be restricted to the stromal components (8) , although the observed tumors in postmenopausal women are frequently of epithelial origin (11) . The mechanism of induction is generally considered to be hormonal (11) , and, in fact, a significant number of postmenopausal women on TAM therapy show estrogen-like changes (7, 25) . TAM induces uterine cancer in neonatally treated mice (32) , and in the rat it is a strong liver carcinogen (13, 19, 35) . TAM binds to DNA as a consequence of DNA-reactive properties (15, 30) , and, thus, it is not possible to exclude the involvement of a direct TAM-related initiation, which has been reported for the rat liver (36) . a-Hydroxytamoxifen, a TAM metabolite, has been shown to induce DNA adducts in organ cultures derived from human endometria (4) ; with a sensitive high-performance liquid chromatography technique (26) , TAM-induced DNA adducts have recently been found in endometrium samples from TAM-treated breast cancer patients (18) .
No increased risk of endometrial tumors has thus far been reported with the use of TOR, but the drug has not been in clinical use for a sufficient enough length of time to draw firm conclusions.
To date, no obvious link exists between preclinical data and endometrial cancers induced by TAM in a clinical setting. Although several studies comparing TAM and TOR (10, 16, 19, 34) have been performed in rats to investigate the differences in the hepatocarcinogenicity of the compounds, only a few comparative preclinical studies have reported uterine findings. In a 1-yr chronic rat study (16) , both drugs induced glandular atrophy, and similar changes were observed in the 2-yr rat carcinogenicity bioassays (13, 23) . However, Mdntyld et al (27) found squamous cell carcinoma in 2 of 104 nonovariectomized Sprague-Dawley (SD) rats after long-term treatment with TAM, but no carcinoma was found with the equimolar dose of TOR. TAM treatment was also associated with squamous metaplasia and dysplasia, with a 9.6% (10/104) and 2.9% (3/104) frequency, respectively, whereas TOR was not. Because both compounds induced an equal reduction of uterine wet weight, the authors discussed whether nonhormonal effects could be responsible for these TAM-induced lesions. Because no additional preclinical studies have reported uterine neoplasia in TAM-treated rats, it is unclear whether these observations reflect a link between preclinical animal data and TAMassociated endometrial tumors in women. Nevertheless, they provide evidence that TAM and TOR might act differently on the rat uterus, either by themselves or indirectly by modulating the production of endogenous es-
trogens.
This study was performed to further evaluate whether these possible differences could be related to differences in their action on the uterine proliferation. The rat uterus is a complex organ with different compartment-specific responses to antiestrogens and, possibly, compartmentspecific estrogen-receptor subtypes (14) . In the rat, the antiestrogens TAM and TOR are partial estrogen agonists, and thus both drugs are likely to affect uterine cell proliferation. Nonovariectomized rats were chosen because the difference between TAM and TOR in inducing squamous metaplasia, dysplasia, and carcinoma was observed in intact animals (27) . In addition, 2 rat strains commonly used in routine toxicity studies, the inbred Fischer 344 (F344) rat and outbred SD rat, were compared to ascertain the more suitable rat strain for future studies of the uterine proliferative actions of TAM and TOR. In a previous report it was shown that the F344 rat was clearly less sensitive to hepatic effects than was the SD rat (36) . The compounds were suspended in 0.5% carboxymethylcellulose, prepared on a weekly basis and stored at 4°C. The dosing volume was kept constant to 1 ml/rat, and the concentrations were adjusted once weekly on the basis of individual body weights so that the daily doses were 5, 10, 20, and 40 mg/kg TAM, 21.2 and 42.4 mg/ kg TOR (equimolar to TAM 20 and 40 mg/kg), and 20 and 40 mg/kg DES. The route of administration was oral by gavage.
Animals and Husbandry. Nonovariectomized female Crl:CD(BR) SD and F344 rats were obtained from Charles River Laboratories, Kingston, NY. The animals were 4 wk old at arrival and 6 wk old when the study commenced. The animals were housed 2 per cage. The rats were kept on a 12-hr light: dark cycle, the room temperature range was 18-26°C, and humidity was maintained at 40-70%. National Institutes of Health-07 powder diet and acidified water were available ad libitum. Animals were maintained and handled according to U.S. Department of Agriculture and National Institutes of Health guidelines for the humane care and use of animals.
The American Health Foundation Research Animals Facility is fully accredited by the American Association for the Accreditation of Laboratory Animal Care. Study Design. Animals were assigned to groups using a random number-generating program. The number of animals per group was 6-8. The duration of the experiment was 12 wk, with an interim sacrifice at 2 wk. The animals designated to be sacrificed at the 2-wk time point were selected using a random number-generating program. The study protocol was approved by the Institutional Animal Care and Use Committee before the study commenced.
Bromodeoxyuridine (BrdU) Administration. BrdU minipumps were implanted beneath the back skin of 3 animals/dose group, 3 days before the scheduled terminal sacrifice. The pumps used were Alzet osmotic pumps (2ml pumps, model no. 2MLl) and were purchased from Alza Corp., Palo Alto, CA. The BrdU concentration was 20 mg/ml. Each pump was set to deliver a total of 13.8 mg per rat.
Postmortem Procedures and Immunohistochemistry. The uterus was studied macroscopically, removed, and fixed in 10% neutral-buffered formalin for more than 48 hours. From the interim 2-wk groups samples from the control and high-dose groups only were processed further, but samples from all groups were included at 12 wk.
The left uterine hom of each animal was embedded longitudinally in paraffin, cut into 5-6-j..Lm sections, and stained for the proliferating cell nuclear antigen (PCNA) or BrdU (12 wk, high doses only). The monoclonal PCNA antibody clone 19A2 was obtained from Coulter Immunology, Inc., and the monoclonal BrdU antibody (Cat. No. 7580) from Becton-Dickinson, Inc. Dilutions used were 1:800 and 1:50, respectively. The immunohistochemistry was performed using standardized methods, and the staining was enhanced (PCNA) by using the microwave technique (9, 12) . The interpretation of the stained slides was made at X250 magnification with an ocular grid disc system appearing as 25 squares (5 X 5) of 20 X 20 p,m in the microscope. In the stroma and myometrium, the total numbers of PCNA-positive cells were counted in 5 subsequent grid systems. All samples studied were initially checked for possible differences between different segments of the uterine horn. No such differences were visible, and the counting was restricted to the middle portion of the longitudinal section to ensure an unbiased evaluation of the samples. The initial grid system to be counted was the one located in the middle of the longitudinal section as measured with the grid system, followed by the 4 posterior grid systems. The total numbers of cells were counted in 5 subsequent squares and then multiplied X5 to give the estimated number of cells in each particular 25-square grid system. The glandular epithelia were evaluated from 5 subsequent grid systems, and the PCNA-positive cells and total numbers of cells were counted. If the number of glands was scarce (< 100 epithelial cells), all glands in the particular section were counted. The luminal epithelium was investigated in 5 subsequent grid systems, comprising altogether at least 25 (20 X 20-j..Lm) squares. If the sample included histologically different epithelial types (columnar singlecell layer or multilayered epithelium), the interpretation was made separately for each epithelial type. The results for each uterine compartment were expressed as proliferation index (PI) = 100% X (PCNA-positive cells/total number of cells).
Statistical Analysis. The mean group body weights were compared with those of the specific control group by Student's t-test. BrdU and PCNA PI were compared between the groups by single classification ANOVA. If significant, it was followed by Dunnett's multiple comparisons test to compare each group to a specific control group. The Student-Newman-Keuls test was used to compare results between the 2 sacrifice time points, between different types of epithelium, or between the 2 rat strains. All tests were performed on p < 0.05, p < 0.01, or p < 0.001 levels of significance.
RESULTS

Body Weight
All treatment groups of both rat strains showed a significant decrease in body weight gain, exceeding 15% by week 12 (Fig. 1 ). DES (20 mg/kg) caused the sharpest reduction of mean body weight (39%) in SD rats, whereas the 2 antiestrogens caused a clearly milder decrease (21-24%). In the F344 rats, this difference was not observed, and all compounds induced a 16-23 % lower mean body weight in treated animals than in control animals, with lowest found in TOR-treated rats. At the doses studied, no dose-dependent decreases of mean body weight were observed.
Overall Uterine Morphology
In both rat strains, TAM and TOR induced stromal and myometrial atrophy and a reduction of the stromal glands. The atrophies were of similar grade at both time points, but the diminishing of glands was complete only at the 12-wk time point. At the 2-wk time point, the remaining glands showed epithelial hypertrophy, and some animals, especially SD rats, had stromal glands with multilayered epithelium occasionally extending into the lumen (Fig. 2 ). This type of epithelium had a time-depen-
-The junction between an endometrial gland (G) and the lumen (L) in a SD rat treated orally with 40 mg/kg TAM for 2 wk. The normal columnar epithelium of the glands is replaced by a multilayer epithelium (ME), which stained intensively with the PCNA antibody in the basal cells. Note the hypertrophy and PCNA negativity of the luminal epithelium (LE) . At the junction between the 2 epithelial types, the luminal columnar epithelium cells show apoptosis (arrowhead). X280. dent increase in the lumen. The multilayered epithelium showed no stratification or intraepithelial differentiation, typical for squamous metaplasia (Fig. 3 ). DES was associated with hypertrophy of stroma and myometrium and epithelial hyperplasia in both rat strains, but the incidence of multilayered epithelium was lower than in the antiestrogen-treated rats. One TAM-treated (40 mg/kg) SD rat and 3 DES-treated (20 mg/kg: 2/5; 40 mg/kg: 1/ 6) F344 rats showed squamous metaplasia.
Uterine Stroma
At the 2-wk time point, no significant differences were observed between the tested compounds (Table I) . Ten weeks later, at the 12-wk time point, no drug-related proliferation was noted with TAM or TOR, but a significant increase of the PI was evident in the DES-treated animals of both strains compared with the corresponding 2-wk group. Additionally, in the lower-dose DES group (20 mg/kg) DES appeared to be more effective in inducing proliferation in the F344 rats than in the SD rats (Table I) .
Myometrium
The PCNA Pls in TAM-and TOR-treated animals were at a very low level at both time points and in both rat strains (Table II) , and no changes were evident between the 2 time points. In the case of DES, a significant elevation of PI occurred between the 2-and 12-wk time points.
Glandular Epithelium
At the 2-wk time point, no differences were evident compared to control groups or between the tested compounds (Table III) . In a few TAM-and TOR-treated animals of both rat strains, the remaining glands focally displayed a multilayered epithelium, which in some cases extended into the lumen and replaced the normal columnar cells (Fig. 2 ). The PCNA antibody strongly stained the basal cells of these epithelia. No glands remained in the uterus of the animals treated with TAM or TOR for 12 wk; thus, the analysis of glandular epithelium was restricted to the animals dosed for 2 wk.
Luminal Epithelium
In contrast to effects in the glandular epithelium, TAM and TOR significantly depressed the PCNA PI in the coy lumnar luminal epithelium in the animals of both strains treated for 2 (Table III) (Table IV) , wherea! DES did not. When the 2 time points were compared, ir SD rats, high doses of TAM (40 mg/kg) and DES (4( mg/kg) produced a significant increase of PI (p < 0.05 ANOVA followed by Student-Newman-Keuls test) at 11 wk, whereas a significant increase of PI was not seen ii TOR-treated animals or in the control group. Howevei the PI in the TAM and the TOR groups did not reac that of the control groups after 12 wk of treatment. i similar comparison could not be made with the F344 rat! because the control values differed significantly betwee the 2 time points, presumably because of different stage of the estrous cycle.
The uterine luminal epithelium (LE) in a F344 rat treated orally with 20 mg/kg DES for 12 wk, showing squamous cell metaplasia The basal cell layer is strongly stained with the PCNA antibody. Note the clear differentiation in the DES-exposed epithelium as the cells migrate toward the surface, including superficial stratification and keratinization (arrowhead). L = lumen, S = stroma. X 125.
The PCNA PI of the luminal columnar epithelium in TAM-, TOR-, and DES-treated animals of both strains showed a weak dose-dependent increase. This was most obvious between the 2 highest doses, where a doubling of the TAM dose caused a 1.86X (SD rat) or a 1.98X (F344 rat) increase of PI. In TOR-treated animals, the corresponding values were 1.71X and 1.97X, and in DES-treated animals, values were 2.05X and 1.81X, respectively.
In a few of the F344 rats, DES induced squamous metaplasia after 12 wk of treatment. Histologically, the epithelium had different intraepithelial stages of differentiation, superficial stratification, and keratinization, as well as strong PCNA staining of the basal cells (Fig. 3 ). The incidences were as follows: 20 mg/kg DES, 2 of 5, and 40 mg/kg DES, 1 of 6. These histological changes were not observed in TORor TAM-treated rats. However, at both time points, but especially at the 12-wk time point, a focal hyperplastic multilayered epithelium was present in TAM-and TOR-dosed SD rats (Table IV) , similar to that observed in the glands of rats treated for 2 wk. This type of epithelium was occasionally widespread. Histologically the epithelium was different from the DES-induced squamous metaplasias and consisted of uniform large cells with a large round nuclei (Fig. 4a ). One exception was a TAM-treated (40 mg/kg) SD rat, which macroscopically displayed unilaterally extensive dilation of the uterine horn and which microscopically exhibited a mild squamous metaplasia (Fig. 4b) . The PCNA-positive cells were typically located in the basal layer of the hyperplastic multilayered epithelium (Fig. 4) , and the PI of these cells was significantly higher in high-dose TAM (40 mg/kg) and high-dose TOR (42.4 mg/kg) compared with the columnar epithelium (Table IV) . Both compounds showed a tendency toward a dose-dependent increase of PI of these basal cells, but no significant differences were observed between the 2 drugs. Only I DES-treated (20 mg/kg) SD rat showed this kind of epithelial response. A similar but reduced incidence of these epithelial responses was also observed in TAM-and TOR-treated F344 rats (Table IV ). Contrary to the SD rat, in the F344 rat strain, no significant differences of the PI were evident between the normal columnar and the basal cells of the multilayered epithelia.
Comparison with BrdU Labeling
The pattern of labeling with BrdU was the same as that for PCNA in the stroma and myometrium. However, in contrast to PCNA, BrdU showed an enhanced PI in the columnar luminal epithelium of TAM-, TOR-, and DES-treated animals of both strains (Table V) . In F344 rats, TAM was associated with a lower increase in PI compared with TOR (p < 0.05), and both antiestrogens had less of an increase in PI than DES (p < 0.05, ANO- VA followed by Student-Newman-Keuls test).
DISCUSSION
Proliferative effects in the rat uterus were documented for the antiestrogens TAM and TOR and for the estrogen agonist DES. Nonovariectomized rats were used because the only available nonclinical reports of TAM-related uterine neoplasias were from studies performed in intact rats (27) and mice (32) . Thus, because of the functioning estrous cycle, effects of PCNA and BrdU PI varied significantly among the control animals. However, continued treatment with antiestrogens is known to abolish the cycle, and the vaginal epithelium normally retains a constant histology. In TOR-treated animals, this has been observed at a dose as low as 0.1 mg/kg/day in a 1-yr chronic rat study (33) . The uterine proliferation observed in the treated animals is therefore likely not to have been affected by hormone cyclicity. Nevertheless, the presence of intact ovaries may have contributed to an unknown level of endogenous estrogens. At least in the case of Comparisons were done by ANOVA followed by Dunnett's multiple comparisons test (~) or Student-Newman-Keuls test (e and J). a Dose of compound, mg/kg/day. b Carboxymethylcellulose (0.5%). C Number of specimens studied. d p < 0.05 compared to control. e p < 0.001 between the types of epithelium. f p < 0.01 between the types of epithelium. TAM-and TOR-exposed rats, this was probably lower than in the control animals because TAM is known to decrease the ovarian production of E2 (22) . A prolonged administration of TAM in intact female rats also lowers the circulating prolactin levels to a level similar to that found in ovariectomized animals (22) . All 3 compounds, but especially DES (in the SD rat), showed a time-related decrease in body weight exceeding 15%. A food restriction that induces a 15% reduction in body weight is known to modulate (usually decrease) tumor incidence in rats and mice (6) . Furthermore, a body weight decrease of this magnitude may cause lengthening of the estrous cycles without an increase in cyclicity ( 1 ) . The rat, but not the mouse, is largely resistant to adverse reproductive changes resulting from body weight loss (6). The uterine atrophies described in this study are therefore not associated with the observed loss in body weight. TAM and TOR had equivalent antiestrogenic inhibition of cell proliferation in the rat uterine stroma and myometrium, whereas the synthetic estrogen DES induced cell proliferation in these compartments. This is in agreement with previous studies (13, 16, 23) reporting TAMor TOR-related uterine atrophies. The etiology of these atrophies might be either a direct binding of the antiestrogens to the estrogen receptors of these cells or an indirect atrophy due to either an impaired ovarian function observed in TAM-and TOR-treated rats or the lengthening of the estrous cycle, which leads to decreased estrogen in the uterus due to decreases in gonadotropinreleasing hormone (GnRH) and follicle-stimulating hormone/luteinizing hormone (FSH/LH) suppression. With continuous administration of TAM or TOR, the ovaries are characterized by an increased number of large, occasionally cystic follicles, indicating a delayed or inhibited ovulation and a corresponding decrease in number of (or even a total absence of) luteal glands (16, 23) . Because follicular development is not totally interrupted in TORor TAM-treated rats, these histologic features of the ovaries indicate a diminished LH secretion but a sufficient secretion of FSH from the pituitary. A decreased blood level of LH would also cause decreased secretion of ovarian estrogens, thereby resulting in atrophy of the estrogen-sensitive stromal and muscular uterine compartments. Therefore, it seems likely that TOR-and TAMinduced uterine stromal and myometrial atrophies are at least partly a result of decreased ovarian estrogen production, also known from pharmacological studies on TAM (22) . Alternatively, reduction in body weight leads to a decrease in circulating carrier proteins and decreased estrogen clearance through the liver, achieving reduced circulating estrogen and leading to reduced GnRH and LH (20) . The results also indicate that these partial agonistic antiestrogens do not have any significant agonistic effects on the uterine stroma or myometrium in intact rats, even when administered at excessive doses.
Interestingly, TAM and TOR inhibited PCNA PI in the luminal but not in the glandular epithelium at the 2-wk time point. Nevertheless, after 12 wk of treatment, the endometrial glands disappeared. The decreased PI in the columnar luminal epithelium might be the result of an atrophic stromal tissue, because the signals for estrogeninduced epithelial proliferation are mediated through the stromal cells (3) . On the other hand, the unaffected proliferation rate in the glandular epithelium, despite stromal atrophy, would indicate that these antiestrogens have a different effect in luminal than in glandular epithelium. When the BrdU method was used, the findings in the stroma and myometrium were similar to those observed by PCNA; while in contrast to findings with the PCNA method, the BrdU Pls were clearly elevated in the columnar luminal epithelium of TAM-and TOR-treated rats. The BrdU method labels the S-phase cells during a specific period of time (3 days in this study), whereas when formalin-fixed with PCNA antibody, cells in the G1, S, G,, and M phases are counted at a specific time point (9) . Thus, it appears that TAM and TOR induce a slightly increased DNA synthesis in the luminal epithelial cells over a longer period of time, while at the same time the number of quiescent cells at a given time point is very high. This is consistent with the finding that antiestrogen 12 wk. The columnar epithelium is replaced by a focal hyperplastic multilayer epithelium, which is strongly PCNA positive in the basal cell layer. The epithelium consists of large cells with prominent round nuclei. Note the sloughing of superficial cells (arrowheads) and the mild squamous metaplasia of the TAMtreated rat (compared with Fig. 3 ). X 125. treatment is associated with prolonged epithelial hypertrophy but not hyperplasia of uterine epithelial cells (28, 29) . The findings in the glandular epithelium are also consistent with the observations by Martin (28, 29) that TAM is a pure antagonist in the luminal epithelium but induces a weak increase of the proliferation rate in the glandular epithelium that is outweighed by a lethal cytotoxic effect, leading to a gradual diminishing of the endometrial glands. Therefore, it is also possible that these differences in the epithelial responses to TAM, Another possible difference between the 2 antiestrogens was that there was a single case of mild squamous metaplasia in a TAM-treated (40 mg/kg for 12 wk) SD rat. Although the histologic appearance was not as clear as in the DES-related squamous metaplasias, the epithelium showed features reported earlier by Mdntyld et al (27) . In that study, TAM (45 mg/kg), but not the equimolar dose of TOR, induced epithelial changes that seemed to progress toward malignancies. No such findings have been reported in other long-term rat studies (13, 16) , and no indications of malignancies were observed in the present study. Because the SD rat is an outbred strain, this contradiction might be related to genetic differences between strains from different breeders. It is known that the hepatocarcinogenic effects of TAM are not hormone associated (36) . In view of the high DNA reactivity of TAM, it can be speculated that TAM-related uterine neoplasia in the rat could occur under certain conditions (high dose, animal strain) as a combination of persistent proto-oncogene expression (31) , the focally induced basal cell proliferation and genotoxicity. If so, the nongenotoxic TOR would probably be also nontumorigenic in the rat uterus. However, further detailed studies would be necessary to elucidate this issue and the relevance to humans.
In premenopausal women, TAM has a proliferative effect that seems to be mediated mainly by the stromal component (8) . Thus, the uterine response to TAM is different in the nonovariectomized rat, in which the proliferation appears to be restricted to the epithelia.
In conclusion, both antiestrogens showed a similar hormone-related induction or inhibition of uterine cell proliferation in intact female rats. The induction was of a focal nature and restricted to a hyperplastic multilayertype of epithelium, probably developing from the atrophic endometrial glands. Additionally, this study confirmed the striking differences between the luminal and glandular epithelial responses to the antiestrogens. Also, based on this study, the uterus of the F344 rat appears to be slightly more sensitive to high doses of DES than that of the SD rat, as manifested by more prominent proliferation of the myometrium and stroma and increased squamous metaplasias of the luminal epithelium. In contrast, the antiestrogens TAM and TOR increased cell proliferation mainly focally in the uterine luminal epithelium of SD rats. Thus, the SD rat seems to be the better strain to use to investigate possible estrogenic side effects of novel triphenylethylene antiestrogens.
